• 
  Françoise Revillion, Michael T. Parsons, Emma Tudini, Hongyan Li, Eric Hahnen, et al.. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. Human Mutation, 2019, 40 (9), pp.1557-1578. ⟨10.1002/humu.23818⟩. ⟨hal-02194510⟩
• 
  Olivier de Hertogh, Guillaume Le Bihan, Thomas Zilli, Samuel Palumbo, Marjory Jolicoeur, et al.. Consensus Delineation Guidelines for Pelvic Lymph Node Radiation Therapy of Prostate Cancer : On Behalf of the Francophone Group of Urological Radiation Therapy (GFRU). International Journal of Radiation Oncology, Biology, Physics, 2024, 118 (1), pp.29-40. ⟨10.1016/j.ijrobp.2023.07.020⟩. ⟨hal-04813729⟩
• 
  Ingrid Masson, Laurène Larriviere, Marc-André Mahé, David Azria, Pascal Pommier, et al.. Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancer. Clinical and Translational Radiation Oncology, 2024, 44, pp.100702. ⟨10.1016/j.ctro.2023.100702⟩. ⟨hal-04813716⟩
• 
  Nicolas Penel, Olivier Mir, Jennifer Wallet, Isabelle Ray-Coquard, Axel Le Cesne, et al.. A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib. European Journal of Cancer, 2020, 126, pp.45-55. ⟨10.1016/j.ejca.2019.12.001⟩. ⟨hal-03623680⟩
• 
  Loig Vaugier, Elvire Martin-Mervoyer, Loic Ah-Thiane, Martin Langé, Luc Ollivier, et al.. How to contour the different heart subregions for future deep-learning modeling of the heart: A practical pictorial proposal for radiation oncologists. Clinical and Translational Radiation Oncology, 2024, 45, pp.100718. ⟨10.1016/j.ctro.2023.100718⟩. ⟨hal-04791592⟩
• 
  Olivier Bylicki, Florian Guisier, Arnaud Scherpereel, Catherine Daniel, Aurélie Swalduz, et al.. Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04–2021) trial. Lung Cancer, 2024, 194, pp.107866. ⟨10.1016/j.lungcan.2024.107866⟩. ⟨hal-04751314⟩
• 
  J. Guigay, C. Ortholan, D. Vansteene, D. Cupissol, C. Even, et al.. Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial. The Lancet. Healthy longevity, 2024, 5 (3), pp.e182--e193. ⟨10.1016/s2666-7568(23)00284-2⟩. ⟨hal-04661312⟩
• 
  Joël Guigay, Hervé Le Caer, François-Régis Ferrand, Lionel Geoffrois, Esma Saada-Bouzid, et al.. Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial. The Lancet. Healthy longevity, 2024, 5 (6), pp.e392-e405. ⟨10.1016/S2666-7568(24)00048-5⟩. ⟨hal-04578230⟩
• 
  Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, Christine Chevreau, Nicolas Penel, et al.. Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma. New England Journal of Medicine, 2024, 391 (9), pp.789-799. ⟨10.1056/NEJMoa2403394⟩. ⟨inserm-04761524⟩
• 
  Sue Cheeseman, Bethany Levick, Will Sopwith, Hayley Fenton, Eun Ji Nam, et al.. Ovarian Real-World International Consortium (ORWIC): A multicentre, real-world analysis of epithelial ovarian cancer treatment and outcomes. Frontiers in Oncology, 2023, 13, pp.1114435. ⟨10.3389/fonc.2023.1114435⟩. ⟨hal-04756405⟩
• 
  Loic Ah-Thiane, Caroline Rousseau, Maud Aumont, Axel Cailleteau, Mélanie Doré, et al.. The Sentinel Lymph Node in Treatment Planning: A Narrative Review of Lymph-Flow-Guided Radiotherapy. Cancers, 2023, 15 (10), pp.2736. ⟨10.3390/cancers15102736⟩. ⟨hal-04755878⟩
• 
  Stéphane J.C. Mancini, Karl Balabanian, Isabelle Corre, Julie Gavard, Gwendal Lazennec, et al.. Deciphering Tumor Niches: Lessons From Solid and Hematological Malignancies. Frontiers in Immunology, 2021, 12, pp.766275. ⟨10.3389/fimmu.2021.766275⟩. ⟨hal-04673450⟩
• 
  Gunjan Kayal, Nathaly Barbosa, Carlos Calderón Marín, Ludovic Ferrer, José-Alejandro Fragoso-Negrín, et al.. Quality Assurance Considerations in Radiopharmaceutical Therapy Dosimetry Using PLANETDose: An International Atomic Energy Agency Study. Journal of Nuclear Medicine, 2024, 65 (1), pp.125-131. ⟨10.2967/jnumed.122.265340⟩. ⟨hal-04753484⟩
• 
  Marcela Carausu, Matthieu Carton, Luc Cabel, Anne Patsouris, Christelle Levy, et al.. Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database. Therapeutic Advances in Medical Oncology, 2022, 14, pp.175883592210770. ⟨10.1177/17588359221077082⟩. ⟨hal-03867853⟩
• 
  Fabienne Lesueur, Noura Mebirouk, Yue Jiao, Laure Barjhoux, Muriel Belotti, et al.. GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers. Frontiers in Oncology, 2018, 8, pp.490. ⟨10.3389/fonc.2018.00490⟩. ⟨hal-01926758⟩
• 
  Timothy Rebbeck, Tara Friebel, Eitan Friedman, Ute Hamann, Dezheng Huo, et al.. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Human Mutation, 2018, 39 (5), pp.593-620. ⟨10.1002/humu.23406⟩. ⟨hal-02351570⟩
• 
  Marie Paule Sablin, Pierre Gestraud, Sarah Flora Jonas, Constance Lamy, Magali Lacroix-Triki, et al.. Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors. British Journal of Cancer, In press, ⟨10.1038/s41416-024-02804-6⟩. ⟨hal-04683939⟩
• 
  Jean Michel Lecerf, Carine Delayre, Océane Moulenq, Gregory Ninot, Bruno Raynard, et al.. Le plaisir alimentaire chez le patient traité pour un cancer Auteurs. Nutritions et Endocrinologie, 2024, Hors série, pp.25-28. ⟨hal-04684545⟩
• 
  Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, Christine Chevreau, Nicolas Penel, et al.. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.. Lancet Oncology, 2022, Lancet Oncology, 23 (8), pp.1044-1054. ⟨10.1016/S1470-2045(22)00380-1⟩. ⟨hal-04387055⟩
• 
  Julien Guérin, Amine Nahid, Louis Tassy, Marc Deloger, François Bocquet, et al.. Consore: A Powerful Federated Data Mining Tool Driving a French Research Network to Accelerate Cancer Research. International Journal of Environmental Research and Public Health, 2024, 21 (2), pp.189. ⟨10.3390/ijerph21020189⟩. ⟨inserm-04659888⟩

276

302